IFU (Instructions for Use) is the information a manufacturer supplies with a medical device so users can operate it safely and as intended. It covers intended purpose, warnings, handling, and residual risks. In the EU, it is governed by MDR Annex I, Section 23.4; in the US, it forms part of device labeling under 21 CFR Part 801.
What is IFU (Instructions for Use)?
IFU (Instructions for Use) is the accompanying document, print or electronic, that tells a user how to use a medical device correctly. It sits in the “information supplied with the device” part of a device’s technical documentation, alongside the label. The label identifies the device; the IFU explains how to use it, who it is for, and what to avoid.
An IFU is not a marketing brochure. It is a controlled document that must match the device’s verified and validated performance, its risk file, and its regulatory claims. Change the device and the IFU changes with it under change control.
Why does the IFU (Instructions for Use) matter in medical device development
An IFU is a risk-control measure, not paperwork added at the end. Under ISO 14971 risk management, information for safety—warnings, contraindications, and residual-risk disclosures—is one accepted way to reduce risk that cannot be designed out. If the wording is wrong, the risk control fails, and the harm lands on a patient.
Regulators treat the IFU as evidence. In an EU MDR technical documentation review or an FDA inspection, reviewers read the IFU against your intended purpose, clinical evaluation, and usability file. Mismatches, such as a claim the clinical data does not support, a missing warning, or a symbol with no explanation, are common findings that hold up market access. Rework late in a program is also expensive: it forces re-translation, repackaging, and sometimes re-validation of usability.
What an IFU must contain
The content is not left to the writer’s judgment. In the EU, MDR 2017/745 Annex I, Section 23.4 lists the required particulars; in the US, the IFU falls under device labeling in 21 CFR Part 801, which requires adequate directions for use. Typical elements include:
- Manufacturer name and address, plus (in the EU) the UDI and Basic UDI-DI
- Intended purpose, intended users, and intended patient population.
- Warnings, precautions, contraindications, and residual risks
- Step-by-step directions for safe use, including any required accessories
- Handling, storage, installation, and any cleaning, disinfection, or sterilization steps
- Performance characteristics and, for implantables and Class III devices, a link to the Summary of Safety and Clinical Performance (SSCP)
- The issue or revision date
Several horizontal standards shape how the IFU is written. IEC/IEEE 82079-1:2019 sets principles for preparing information for use, including readability and structure. ISO 15223-1 governs permitted symbols, and ISO 20417 covers information supplied by the manufacturer. The IFU is validated through usability engineering under IEC 62366-1 because an instruction that users cannot follow is itself a use-related risk.
eIFU: providing instructions electronically
Manufacturers can supply instructions electronically (eIFU) instead of on paper under Commission Implementing Regulation (EU) 2021/2226. That regulation was amended by Implementing Regulation (EU) 2025/1234, in force from July 2025, which removed the earlier device-category limits. eIFU is now available for most professional-use devices when a documented risk analysis supports it, and for software, the instructions can sit in the software itself. IVDs are handled separately under the IVDR.
Common challenges and best practices
The most frequent mistake is writing the IFU as an afterthought, copied from a previous product and lightly edited. That is how stale warnings and unsupported claims survive into a submission. Draft the IFU from the risk file and the intended purpose instead.
Watch the reading level. Regulators and IEC 62366-1 expect instructions matched to the real user, clinician, or layperson. Overlong sentences and unexplained jargon are use hazards, not style problems.
Control translations tightly. Every EU market needs the IFU in its national language, and a translation error carries the same risk as an error in the source. Keep the IFU, label, risk file, and clinical evidence aligned as one set, and version every IFU against a device revision so an auditor can trace which instruction shipped with which device.
How SJML helps with IFU (Instructions for Use)
Syrma Johari MedTech (SJML) supports IFU work as part of its design and regulatory services. Its QARA “Compliance-as-a-Service” team handles labeling and packaging within regulatory sustenance, including IFU and eIFU creation, global labeling strategy, content updates, and UDI compliance. The team also supports technical documentation and DHF preparation for FDA 510(k), CE marking, and EU MDR/IVDR routes. Usability engineering under IEC 62366-1 and risk management under ISO 14971 are built into the design process, so instructions trace back to user needs and the risk file rather than being added at the end.
Frequently asked questions
The label is the identifying information on or attached to the device or its packaging, such as device name, manufacturer, UDI, and lot number. The IFU is a separate document explaining how to use the device safely and for its intended purpose. Both count as “labeling,” but they serve different functions.
Almost always, though not universally. EU MDR allows an IFU to be omitted or abbreviated for Class I and Class IIa devices only if they can be used safely without one. The FDA requires adequate directions for use under 21 CFR Part 801, with specific exemptions for certain prescription devices.
Yes, within limits. In the EU, Regulation (EU) 2021/2226, as amended by 2025/1234, permits electronic IFU (eIFU) for most devices intended for professional users when a risk analysis supports it. Lay-user devices generally still need paper, except for software, where instructions can be delivered in the software itself.
IEC/IEEE 82079-1:2019 is the horizontal standard for preparing information for use, covering structure, clarity, and completeness. For medical devices, content requirements come from EU MDR Annex I Section 23.4 or FDA 21 CFR Part 801, symbols from ISO 15223-1, and usability validation from IEC 62366-1.
An inadequate IFU is a common audit and technical documentation finding. Reviewers flag missing warnings, unsupported claims, unexplained symbols, or instructions that do not match the risk file. Findings can delay CE certification or FDA clearance and, after launch, feed into complaints, corrective actions, or field safety actions.
